Company intelligence / Profile preview

CVI Pharmaceuticals (Shanghai) Co Ltd

Palo Alto, California, United States

Ownership: Private
Development stage: Other

Overview

The lead program, CVI-LM001, is a first-in-class oral PCSK9 modulator with completed positive Phase 2 proof-of-concept trial in China for hypercholesterolemia; demonstrated robust reduction of LDL-C and liver fat, favorable safety and pharmacokinetics in clinical and preclinical studies

Therapeutic areas: CardiovascularGastroenterology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

CVI-2742

Unknown

Partnerships

Exclusive China licensing agreement with Yangtze River Pharmaceuticals Group for CVI-LM001

Beyond the preview

Go deeper on CVI Pharmaceuticals (Shanghai) Co Ltd.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CVI Pharmaceuticals (Shanghai) Co Ltd.

Explore the full profile